Literature DB >> 15954133

Clinical characteristics in early Parkinson's disease in a central California population-based study.

Gail A Kang1, Jeff M Bronstein, Donna L Masterman, Matthew Redelings, Jarrod A Crum, Beate Ritz.   

Abstract

There is considerable variation in the phenotypic appearance of individuals with idiopathic Parkinson's disease (PD), which may translate into differences in disease progression in addition to underlying disease etiology. In this publication, we report on the demographic and clinical characteristics of 162 individuals diagnosed with clinically probable PD from January 1998 to June 2003 who resided in predominantly rural communities in central California. The majority of the subjects were Caucasian, male, and between 60 and 79 years of age. The akinetic-rigid and tremor-dominant subtypes were more common than the mixed subtype. The majority of subjects displayed motor signs of rigidity (92.0%), bradykinesia (95.7%), and gait problems (87.0%), whereas less than half (43.3%) of the subjects displayed a tremor. Three fourths of patients received a Hoehn and Yahr Scale score of Stage 2 or higher. One third of the patients were treated with levodopa, and patients under 60 years of age were more likely to be treated with dopamine agonists. Within 3 years after first diagnosis, 13% of subjects showed some signs of depression and 17% of subjects met criteria for mild dementia. Among our subjects, 17.3% reported a family history of PD in first- or second-degree relatives,15.4% a family history of essential tremor, and 14.2% of Alzheimer's disease. This study represents the most extensive phenotypic description of rural U.S. residents in the initial stages of PD who were recruited in a population-based manner; future follow-up may provide valuable information regarding the prognostic indication of these symptoms/signs and improve our understanding of the underlying etiology of PD. (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Year:  2005        PMID: 15954133      PMCID: PMC3643967          DOI: 10.1002/mds.20513

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  44 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

2.  Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.

Authors:  Nico J Diederich; Charity G Moore; Sue E Leurgans; Teresa A Chmura; Christopher G Goetz
Journal:  Arch Neurol       Date:  2003-04

3.  Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease.

Authors:  Alexei Korchounov; Hayo I Schipper; Irina S Preobrazhenskaya; Kirn R Kessler; Nikolay N Yakhno
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

4.  A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease.

Authors:  A H Rajput; K P Offord; C M Beard; L T Kurland
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

5.  Family history of tremor in Parkinson's disease compared with those of controls and patients with idiopathic dystonia.

Authors:  A E Lang; C Kierans; R D Blair
Journal:  Adv Neurol       Date:  1987

6.  Functional decline in Parkinson disease.

Authors:  J Jankovic; A S Kapadia
Journal:  Arch Neurol       Date:  2001-10

7.  Neurodegenerative disease: a different view of diagnosis.

Authors:  J Hardy; K Gwinn-Hardy
Journal:  Mol Med Today       Date:  1999-12

Review 8.  Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease.

Authors:  David Botstein; Neil Risch
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

9.  Parkinson's disease in China. Coordinational Group of Neuroepidemiology, PLA.

Authors:  Y S Wang; Y M Shi; Z Y Wu; Y X He; B Z Zhang
Journal:  Chin Med J (Engl)       Date:  1991-11       Impact factor: 2.628

10.  Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease.

Authors:  Frank L Mastaglia; Russell D Johnsen; Michelle L Byrnes; Byron A Kakulas
Journal:  Mov Disord       Date:  2003-01       Impact factor: 10.338

View more
  98 in total

1.  Occupational pesticide use and Parkinson's disease in the Parkinson Environment Gene (PEG) study.

Authors:  Shilpa Narayan; Zeyan Liew; Jeff M Bronstein; Beate Ritz
Journal:  Environ Int       Date:  2017-08-02       Impact factor: 9.621

2.  Familial associations of Alzheimer disease and essential tremor with Parkinson disease.

Authors:  S Costello; Y Bordelon; J Bronstein; B Ritz
Journal:  Eur J Neurol       Date:  2010-03-17       Impact factor: 6.089

3.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

4.  Geographic model and biomarker-derived measures of pesticide exposure and Parkinson's disease.

Authors:  Beate Ritz; Sadie Costello
Journal:  Ann N Y Acad Sci       Date:  2006-09       Impact factor: 5.691

5.  Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

Authors:  R A Popat; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; V McGuire; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson
Journal:  Eur J Neurol       Date:  2011-01-31       Impact factor: 6.089

6.  Coffee consumption is associated with DNA methylation levels of human blood.

Authors:  Yu-Hsuan Chuang; Austin Quach; Devin Absher; Themistocles Assimes; Steve Horvath; Beate Ritz
Journal:  Eur J Hum Genet       Date:  2017-02-15       Impact factor: 4.246

7.  The association between ambient exposure to organophosphates and Parkinson's disease risk.

Authors:  Anthony Wang; Myles Cockburn; Thomas T Ly; Jeff M Bronstein; Beate Ritz
Journal:  Occup Environ Med       Date:  2014-01-16       Impact factor: 4.402

8.  Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease.

Authors:  Angelika D Manthripragada; Sadie Costello; Myles G Cockburn; Jeff M Bronstein; Beate Ritz
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Authors:  Nir Giladi; Anthony P Nicholas; Mahnaz Asgharnejad; Elisabeth Dohin; Franz Woltering; Lars Bauer; Werner Poewe
Journal:  J Parkinsons Dis       Date:  2016-10-19       Impact factor: 5.568

10.  Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.

Authors:  Naying He; Pei Huang; Huawei Ling; Jason Langley; Chunlei Liu; Bei Ding; Juan Huang; Hongmin Xu; Yong Zhang; Zhongping Zhang; Xiaoping Hu; Shengdi Chen; Fuhua Yan
Journal:  NMR Biomed       Date:  2016-05-18       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.